Combination of an anti-ED - B fibronectin domain antibody - IL-2 fusion protein and gemcitabine

The invention refers to the use of L19IL2 for treatment of pancreatic cancer. In another embodiment, the invention relates to a combination (i) of a fusion protein, comprising an Interleukin 2 part and an antibody part, specifically recognising the extra domain B of fibronectin (ED-B-fibronectin), a...

Full description

Saved in:
Bibliographic Details
Main Authors WAGNER KAROLA, MENSSEN HANS DIETRICH, MENRAD ANDREAS
Format Patent
LanguageEnglish
Published 30.04.2009
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The invention refers to the use of L19IL2 for treatment of pancreatic cancer. In another embodiment, the invention relates to a combination (i) of a fusion protein, comprising an Interleukin 2 part and an antibody part, specifically recognising the extra domain B of fibronectin (ED-B-fibronectin), and (ii) gemcitabine.
Bibliography:Application Number: US20070783274